{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:37:04Z","timestamp":1762083424390,"version":"build-2065373602"},"reference-count":93,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Systemic peripheral T cell lymphomas (PTCL) are a rare and clinically and biologically heterogeneous group of disorders with scarce and generally low-quality evidence guiding their management. In this manuscript, we tackle the current controversies in the front-line treatment of systemic PTCL including (1) whether CNS prophylaxis should be administered; (2) whether CHOEP should be preferred over CHOP; (3) what role brentuximab vedotin should have; (4) whether stem cell transplant (SCT) consolidation should be used and whether autologous or allogeneic; (5) how should molecular subtypes (including DUSP22 or TP63-rearranged ALCL or GATA3 or TBX21 PTCL, NOS) impact therapeutic decisions; and (6) whether there is a role for targeted agents beyond brentuximab vedotin.<\/jats:p>","DOI":"10.3390\/cancers15010220","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T03:18:18Z","timestamp":1672370298000},"page":"220","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-591X","authenticated-orcid":false,"given":"Marc","family":"Sorigue","sequence":"first","affiliation":[{"name":"Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, LUMN, UAB, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Health Medicine, University of Eastern Finland, 70211 Kuopio, Finland"},{"name":"Medical Research Centre and Cancer and Translational Research Unit, Oulu University Hospital and University of Oulu, 90220 Oulu, Finland"},{"name":"Department of Oncology, Kuopio University Hospital, 70210 Kuopio, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_2","unstructured":"Swerdlow, S.H. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: A population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP Versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Angelos, M., Ballard, H., and Barta, S. (2022). Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. J. Pers. Med., 12.","DOI":"10.3390\/jpm12020267"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pileri, S.A., Tabanelli, V., Fiori, S., Calleri, A., Melle, F., Motta, G., Lorenzini, D., Tarella, C., and Derenzini, E. (2021). Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment. Cancers, 13.","DOI":"10.3390\/cancers13184535"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"874462","DOI":"10.3389\/fonc.2022.874462","article-title":"Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry","volume":"12","author":"Mocikova","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chihara, D., Fanale, M.A., Miranda, R.N., Noorani, M., Westin, J.R., Nastoupil, L.J., Hagemeister, F.B., Fayad, L.E., Romaguera, J.E., and Samaniego, F. (2018). The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191461"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2014-12-616961","article-title":"Central nervous system relapse in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study","volume":"126","author":"Ellin","year":"2015","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/0284186X.2015.1118656","article-title":"Central nervous system involvement in T-cell lymphoma: A single center experience","volume":"55","author":"Gurion","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of Patients with Peripheral T-Cell Lymphoma after First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/annonc\/mdq645","article-title":"Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma","volume":"22","author":"Yi","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W","article-title":"Central nervous system involvement in adult T-cell leukemia\/lymphoma","volume":"65","author":"Teshima","year":"1990","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.2021012888","article-title":"Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: Real-world outcomes from 21 US academic institutions","volume":"139","author":"Reed","year":"2022","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: A multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103756","DOI":"10.1016\/j.critrevonc.2022.103756","article-title":"The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis","volume":"176","author":"Lin","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","article-title":"First-line therapy for T cell lymphomas: A retrospective population-based analysis of 906 T cell lymphoma patients","volume":"98","author":"Janikova","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/bloodadvances.2020001581","article-title":"ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project","volume":"5","author":"Shustov","year":"2021","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14740","article-title":"The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study","volume":"178","author":"Cederleuf","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sibon, D. (2022). Peripheral T-Cell Lymphomas: Therapeutic Approaches. Cancers, 14.","DOI":"10.3390\/cancers14092332"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2011985","DOI":"10.1001\/jamanetworkopen.2020.11985","article-title":"Evaluation of the Use of Cancer Registry Data for Comparative Effectiveness Research","volume":"3","author":"Kumar","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2115668","DOI":"10.1001\/jamanetworkopen.2021.15668","article-title":"Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies: A Systematic Review","volume":"4","author":"Banerjee","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of Population-Based Observational Studies with Randomized Trials in Oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"v108","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Gaulard","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"Relander","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study","volume":"27","author":"Reimer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Abeyakoon, C., van der Weyden, C., Harrop, S., Khot, A., Dickinson, M., Yannakou, C.K., and Prince, H.M. (2020). Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12113125"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1182\/bloodadvances.2020003971","article-title":"Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2","volume":"6","author":"Savage","year":"2022","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: A multicenter GELTAMO\/FIL study","volume":"107","author":"Bellei","year":"2022","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: Final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: Prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA2","article-title":"A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108)","volume":"38","author":"Khan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/s41598-020-59908-1","article-title":"Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis","volume":"10","author":"Gera","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/sim.4780030413","article-title":"Using observational data from registries to compare treatments: The fallacy of omnimetrics","volume":"3","author":"Green","year":"1984","journal-title":"Stat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","article-title":"NCCN Guidelines Insights: Non-Hodgkin\u2019s Lymphomas, Version 3.2016","volume":"14","author":"Horwitz","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1007\/s12325-021-01764-0","article-title":"Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort","volume":"38","author":"Kirkwood","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Noring, K., Carlsten, M., Sonnevi, K., and Wahlin, B.E. (2021). The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: A population-based study showing improved outcome. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08225-5"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK\/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"23","author":"Kumar","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Milpied","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/10428194.2021.1999438","article-title":"Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: A Meta-Analysis","volume":"63","author":"Singh","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e219807","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_55","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","article-title":"Outcome of allogeneic transplantation for mature T-cell lymphomas: Impact of donor source and disease characteristics","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","article-title":"Allogeneic stem cell transplantation for peripheral T cell lymphomas: A retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"13","author":"Mamez","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","article-title":"Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: A CIBMTR analysis","volume":"12","author":"Epperla","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Castellar","year":"2014","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","article-title":"DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: A Danish cohort study","volume":"130","author":"Pedersen","year":"2017","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2018-03-838524","article-title":"Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"132","author":"Luchtel","year":"2018","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/bjh.15860","article-title":"Identification of high-risk DUSP 22-rearranged ALK-negative anaplastic large cell lymphoma","volume":"186","author":"Hapgood","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/10428194.2021.1984457","article-title":"Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes","volume":"63","author":"Klairmont","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma\u2013NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021015019","article-title":"DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T-cells in PTCL-NOS","volume":"140","author":"Herek","year":"2022","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.26270","article-title":"Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management","volume":"96","author":"Zain","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"863461","DOI":"10.3389\/fonc.2022.863461","article-title":"Targeting ALK Rearrangements in NSCLC: Current State of the Art","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2015.1064530","article-title":"Genetics of anaplastic large cell lymphoma","volume":"57","author":"Zeng","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_73","first-page":"djt378","article-title":"Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase\u2013Positive Lymphoma Patients","volume":"106","author":"Passerini","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study","volume":"93","author":"Orlov","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children\u2019s Oncology Group Study","volume":"35","author":"Voss","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_77","first-page":"4749452","article-title":"Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma","volume":"2022","author":"Verran","year":"2022","journal-title":"Case Rep. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"100172","DOI":"10.1016\/j.esmoop.2021.100172","article-title":"Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma","volume":"6","author":"Subbiah","year":"2021","journal-title":"ESMO Open"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e2100250","DOI":"10.1200\/PO.21.00250","article-title":"Lymphomatous Meningitis From Anaplastic Lymphoma Kinase+ Anaplastic Large T-Cell Lymphoma Treated with Lorlatinib: A Case Report","volume":"6","author":"Mellacheruvu","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/ajh.26288","article-title":"Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts","volume":"96","author":"Lunning","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: A multicenter phase 1 study","volume":"134","author":"Falchi","year":"2019","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2022-156789","article-title":"Oral Azacytidine in Patients with Relapsed\/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study","volume":"140","author":"Dupuis","year":"2022","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:56:01Z","timestamp":1760147761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/1\/220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15010220"],"URL":"https:\/\/doi.org\/10.3390\/cancers15010220","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}